517 related articles for article (PubMed ID: 16298037)
21. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells.
Zhou S; Turgeman G; Harris SE; Leitman DC; Komm BS; Bodine PV; Gazit D
Mol Endocrinol; 2003 Jan; 17(1):56-66. PubMed ID: 12511606
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.
Levy N; Tatomer D; Herber CB; Zhao X; Tang H; Sargeant T; Ball LJ; Summers J; Speed TP; Leitman DC
Mol Endocrinol; 2008 Feb; 22(2):287-303. PubMed ID: 17962382
[TBL] [Abstract][Full Text] [Related]
23. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
Nuttall ME; Stroup GB; Fisher PW; Nadeau DP; Gowen M; Suva LJ
Am J Physiol Cell Physiol; 2000 Nov; 279(5):C1550-7. PubMed ID: 11029302
[TBL] [Abstract][Full Text] [Related]
24. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
25. A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells.
Sun Y; Kasiappan R; Tang J; Webb PL; Quarni W; Zhang X; Bai W
J Biol Chem; 2014 May; 289(18):12217-31. PubMed ID: 24619425
[TBL] [Abstract][Full Text] [Related]
26. KISS1 is down-regulated by 17beta-estradiol in MDA-MB-231 cells through a nonclassical mechanism and loss of ribonucleic acid polymerase II binding at the proximal promoter.
Huijbregts L; de Roux N
Endocrinology; 2010 Aug; 151(8):3764-72. PubMed ID: 20534720
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
Applanat MP; Buteau-Lozano H; Herve MA; Corpet A
Adv Exp Med Biol; 2008; 617():437-44. PubMed ID: 18497067
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
Liu Z; Shi HY; Nawaz Z; Zhang M
Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
[TBL] [Abstract][Full Text] [Related]
30. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
31. Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells.
Singleton DW; Feng Y; Chen Y; Busch SJ; Lee AV; Puga A; Khan SA
Mol Cell Endocrinol; 2004 Jun; 221(1-2):47-55. PubMed ID: 15223131
[TBL] [Abstract][Full Text] [Related]
32. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
[TBL] [Abstract][Full Text] [Related]
34. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells.
Zhang Y; Zhou G; Wang H; Zhang X; Wei F; Cai Y; Yin D
Oncology; 2006; 71(5-6):446-55. PubMed ID: 17878748
[TBL] [Abstract][Full Text] [Related]
36. Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells.
Wang C; Yu J; Kallen CB
PLoS One; 2008; 3(10):e3523. PubMed ID: 18949048
[TBL] [Abstract][Full Text] [Related]
37. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
38. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
39. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Webb P; Nguyen P; Kushner PJ
J Biol Chem; 2003 Feb; 278(9):6912-20. PubMed ID: 12482846
[TBL] [Abstract][Full Text] [Related]
40. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways.
Syed FA; Mödder UI; Fraser DG; Spelsberg TC; Rosen CJ; Krust A; Chambon P; Jameson JL; Khosla S
J Bone Miner Res; 2005 Nov; 20(11):1992-2001. PubMed ID: 16234973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
